Research programme: cancer therapeutics - Tiziana Life Sciences

Drug Profile

Research programme: cancer therapeutics - Tiziana Life Sciences

Alternative Names: Anti-cancer stem cell agent - Tiziana; Bcl3i molocules - Cardiff University/ Tiziania Life Sciences; CB1; cFLIP inhibitors; JS6; OH 14; TZLS 214; TZLS101

Latest Information Update: 06 Jun 2016

Price : $50

At a glance

  • Originator Cardiff University
  • Developer Cardiff University; Tiziana Life Sciences
  • Class Small molecules
  • Mechanism of Action Apoprotein stimulants; Bcl-X protein inhibitors; Molecular motor protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Colorectal cancer

Most Recent Events

  • 01 Jun 2016 Preclinical trials in Colorectal cancer (Late-stage disease) in United Kingdom (unspecified route)
  • 08 Jan 2016 Tiziana plans a clinical trial for Breast cancer
  • 08 Jan 2016 Tiziana Life Sciences announces intention to submit IND in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top